Allovir, Inc. (ALVR) [Rocket]

Overview

Allovir, Inc. (ALVR)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	4	Brainard Diana (CEO) has filed a Form 4 on Allovir, Inc.
10/05/2023	4	Sinha Vikas (See Remarks) has filed a Form 4 on Allovir, Inc.
10/05/2023	4	Hagen Brett R (Chief Accounting Officer) has filed a Form 4 on Allovir, Inc.
10/03/2023	144	Form 144 - Report of proposed sale of securities:
10/03/2023	144	Form 144 - Report of proposed sale of securities:
10/03/2023	144	Form 144 - Report of proposed sale of securities:
08/21/2023	4	Sinha Vikas (See Remarks) has filed a Form 4 on Allovir, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
Revenues	0.0	0.0	0.2	1.1
Revenue growth		-100.0%	-85.5%
Cost of goods sold	0.0	0.0	0.0	4.7
Gross profit	0.0	0.0	0.2	-3.6
Gross margin			100.0%	-316.8%
Selling, general and administrative	169.8	71.3
Research and development			16.2
General and administrative			10.6	3.0
EBIT	0.0	0.0	-26.7	-3.6
EBIT margin			-16182.4%	-316.8%
Pre-tax income	-171.0	-69.8	-23.8	-2.4
Income taxes	1.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%
Net income	-172.0	-69.8	-23.8	0.0
Net margin			-14447.9%	-0.7%

Diluted EPS	($2.74)	($2.59)	($18.54)	($39.90)
Shares outstanding (diluted)	62.8	26.9	1.3	0.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.